AusperBio, the joint venture of Ausper Biopharma Co. Ltd. and AusperBio Therapeutic, Inc., is proud to announce the successful completion of the first cohort dosing in a groundbreaking Phase 1 clinical trial. This trial is evaluating AHB–137, a potential best-in-class, highly potent ASO targeting all HBV RNA, in both adult healthy volunteers and chronic hepatitis B (CHB) patients in New Zealand. The results so far have been incredibly promising, with AHB-137 showing excellent tolerance in all human subjects. This marks a major step forward in the development of an effective and efficient treatment for CHB patients.
We are delighted to announce the commencement of the first-in-human dosing of AHB-137 in New Zealand! ASO drug targeting HBsAg production has demonstrated immense potential to become a cornerstone therapy for the functional cure of CHB. AHB-137 has displayed the best-in-class activity in reducing HBsAg across multiple preclinical models. With over 250 million people infected with HBV globally, CHB is an exceedingly difficult-to-cure viral infection that can lead to liver cirrhosis and cancer. Current treatments can only suppress HBV replication, but the cure rate is low. As such, there is a pressing need to develop safe and finite therapies for HBV cure – and AHB-137 may be the key to transforming the treatment of CHB patients!
AusperBio is thrilled to announce the completion of the first cohort dosing of AHB-137, a significant milestone in its three-year journey. AusperBio’s Chief Scientific Officer and co-founder, Dr. Chris Yang, stated, “We are excited to continue advancing our HBV cure candidates into clinic studies in 2023 and utilizing our proprietary and powerful ASO platform to explore non-viral targets in the liver and beyond!”
The upcoming Phase 1 clinical trial of AHB-137 is an exciting opportunity to investigate the safety, tolerability, and pharmacokinetics of this promising drug in healthy volunteers and its initial efficacy in patients with chronic hepatitis B. Preclinical studies have shown AHB-137 to be highly effective in reducing HBsAg with a favorable safety profile, and two presentations will be made at a scientific congress in June to discuss these detailed results. This is a unique chance to explore the potential of AHB-137 to trigger the degradation of all HBV RNA.
AusperBio is a pioneering biopharmaceutical company that is working to revolutionize the treatment of HBV infections. With operations in China and the USA, the company has developed a proprietary ASO technology platform that enables targeted liver therapies with the potential to be applied beyond just the liver. AusperBio’s mission is to become a world-leading developer of antiviral therapeutics, leveraging their advanced oligonucleotide therapies, therapeutic antibodies, and mRNA vaccines to tackle a wide range of unmet medical needs.